Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate.

Ryuta Uraki Mutsumi Ito Maki Kiso Seiya Yamayoshi Kiyoko Iwatsuki-Horimoto Yuri Furusawa Yuko Sakai-Tagawa Masaki Imai Michiko Koga Shinya Yamamoto Eisuke Adachi Makoto Saito Takeya Tsutsumi Amato Otani Tetsuhiro Kikuchi Hiroshi Yotsuyanagi Peter J Halfmann Andrew Pekosz Yoshihiro Kawaoka

Lancet Infect Dis

Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; Pandemic Preparedness, Infection and Advanced Research Center, University of Tokyo, Tokyo 108-8639, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA. Electronic address:

Published: April 2023

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908083	PMC
http://dx.doi.org/10.1016/S1473-3099(23)00070-1	DOI Listing

Publication Analysis

Top Keywords

antiviral bivalent

bivalent vaccine

vaccine efficacy

efficacy omicron

omicron xbb15

xbb15 isolate

antiviral

vaccine

efficacy

omicron

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!